MAIA Biotechnology, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by MAIA Biotechnology, Inc. on December 23, 2024. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Chicago, Illinois. Its common stock trades on the NYSE American under the symbol "MAIA".
Key Financial Metrics
This filing does not contain standard financial statements, revenue, profit, cash flow, or margin data. The only financial figures disclosed relate to the Company's At The Market (ATM) equity offering program:
- Previous ATM Cap: $11,280,000
- New ATM Cap: $30,000,000
- Shares Sold to Date: Approximately $10,111,994 in aggregate sales price
Material Changes
On December 23, 2024, the Company increased the maximum aggregate offering price of shares issuable under its Sales Agreement with H.C. Wainwright & Co. from $11,280,000 to $30,000,000. A prospectus supplement was filed to cover the increased aggregate amount of $30,000,000.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, management commentary on future operations, or a discussion of risks and contingencies beyond the standard legal opinion regarding the legality of the share issuance. The primary event is the expansion of the Company's ability to raise capital through the existing ATM facility.
Key Facts for Investor Verification
- Verify the current share price and trading volume to assess the potential dilution impact of the expanded $30,000,000 ATM facility.
- Review the Company's most recent 10-Q or 10-K to understand current cash reserves and burn rate, as this filing does not disclose liquidity status.
- Confirm the remaining capacity under the new $30,000,000 cap after accounting for the $10,111,994 already sold.
- Check for any subsequent filings regarding the actual issuance of shares under the new cap.